Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 19,386 shares, a drop of 71.5% from the January 15th total of 68,026 shares. Currently, 1.1% of the company’s shares are sold short. Based on an average daily volume of 72,538 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 72,538 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.1% of the company’s shares are sold short.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wall Street Zen lowered Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Indaptus Therapeutics currently has an average rating of “Sell”.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities & Exchange Commission. 7.06% of the stock is owned by institutional investors.

Indaptus Therapeutics Price Performance

Shares of INDP stock traded up $0.11 during mid-day trading on Friday, hitting $1.76. 23,812 shares of the stock traded hands, compared to its average volume of 84,894. The stock has a market cap of $3.95 million, a P/E ratio of -0.06 and a beta of 0.98. The stock’s fifty day moving average is $2.48 and its two-hundred day moving average is $3.67. Indaptus Therapeutics has a 52-week low of $1.52 and a 52-week high of $47.60.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share for the quarter, beating the consensus estimate of ($4.17) by $1.19. As a group, equities analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.